19.44
+1.01
(5.48%)
May 23 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 17.76 - 20.00 |
| 52 week | 15.13 - 25.40 |
| Open | 18.16 |
| Vol / Avg. | 4.71M/3.10M |
| Mkt cap | 3.59B |
| P/E | - |
| Div/yield | - |
| EPS | -1.35 |
| Shares | 184.69M |
| Beta | 1.23 |
| Inst. own | 84% |
Events
Jul 29, 2013
Q2 2013 ARIAD Pharmaceuticals, Inc. Earnings Release
Jun 20, 2013
ARIAD Pharmaceuticals, Inc. Annual Shareholder Meeting
- 10:00AM EDT -
Jun 11, 2013
ARIAD Pharmaceuticals, Inc. at Goldman Sachs Healthcare Conference
Jun 5, 2013
ARIAD Pharmaceuticals, Inc. at Jefferies Global Healthcare Conference
May 30, 2013
ARIAD Pharmaceuticals, Inc. at Deutsche Bank dbAccess Health Care Conference
- 10:00AM EDT -
May 20, 2013
ARIAD Pharmaceuticals, Inc. at UBS Global Healthcare Conference -
May 14, 2013
ARIAD Pharmaceuticals, Inc. at Bank of America Merrill Lynch Health Care Conference -
May 7, 2013
Q1 2013 ARIAD Pharmaceuticals, Inc. Earnings Conference Call -
Apr 4, 2013
ARIAD Investor Conference Call
Mar 13, 2013
ARIAD Pharmaceuticals, Inc. at Barclays Healthcare Conference -
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -1000.46% | -39582.80% |
| Operating margin | -998.59% | -36749.11% |
| EBITD margin | - | -35260.39% |
| Return on average assets | -82.01% | -88.19% |
| Return on average equity | -108.80% | -132.66% |
| Employees | 300 | - |
| Carbon Disclosure Rating | - | - |
Address
26 Landsdowne Street
CAMBRIDGE, MA 02139-4234
United States - Map
+1-617-4940400 (Phone)
+1-617-4948144 (Fax)
CAMBRIDGE, MA 02139-4234
United States - Map
+1-617-4940400 (Phone)
+1-617-4948144 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
ARIAD Pharmaceuticals, Inc. (ARIAD) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients. ARIAD�s first medicine, Iclusig, is approved in the United States for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior TKI therapy. As of January 11, 2013, additional clinical trials of Iclusig in other cancers were ongoing. As of January 11, 2013, ARIAD also studied AP26113, another molecularly targeted medicine, in certain forms of lung cancer.
Officers and directors
| Harvey J. Berger M.D. | Chairman of the Board, President, Chief Executive Officer | |
| Edward M. Fitzgerald | Chief Financial Officer, Executive Vice President, Treasurer | |
| Raymond T. Keane Esq. | Senior Vice President, General Counsel, Secretary and Chief Compliance Officer | |
| David L. Berstein Esq. | Senior Vice President, Chief Intellectual Property Officer | |
| Daniel M. Bollag Ph.D. | Senior Vice President - Regulatory Affairs and Quality | |
| Maria E. Cantor | Senior Vice President - Corporate Affairs | |
| Pierre F. Dodion M.D. | Senior Vice President - Corporate Development and Operations | |
| Martin J. Duvall | Senior Vice President - Commercial Operations | |
| Frank G. Haluska M.D., Ph.D. | Senior Vice President - Clinical Research and Development and Chief Medical Officer | |
| Timothy P. Clackson Ph.D. | President - Research and Development, Chief Scientific Officer |